Ocrelizumab

Category: Immunosuppressive



Ocrelizumab Overview

Ocrelizumab (trade name Ocrevus) is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate.[1] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.[1] It was approved by the FDA in March 2017 as a treatment for multiple sclerosis, and the first FDA approved drug for the primary progressive form of MS; it was discovered and developed and is marketed...

Read more Ocrelizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ocrelizumab

Recent Ocrelizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ocrelizumab
  • Injection: 30mg/1ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Ocrelizumab or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA